Log in

NASDAQ:URGNUrogen Pharma Stock Price, Forecast & News

$24.88
-0.48 (-1.89 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.79
Now: $24.88
$25.61
50-Day Range
$23.47
MA: $26.13
$29.70
52-Week Range
$13.12
Now: $24.88
$37.08
Volume104,700 shs
Average Volume218,764 shs
Market Capitalization$519.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.
Read More
Urogen Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
CUSIPN/A
Phone646-768-9780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales25,995.87
Book Value$8.63 per share

Profitability

Net Income$-105,150,000.00

Miscellaneous

Employees70
Market Cap$519.92 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

How has Urogen Pharma's stock been impacted by COVID-19 (Coronavirus)?

Urogen Pharma's stock was trading at $23.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, URGN stock has increased by 4.3% and is now trading at $24.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Urogen Pharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urogen Pharma.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Urogen Pharma.

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($1.79) earnings per share for the quarter, missing the consensus estimate of ($1.62) by $0.17. View Urogen Pharma's earnings history.

What price target have analysts set for URGN?

6 Wall Street analysts have issued 1-year price objectives for Urogen Pharma's stock. Their forecasts range from $37.00 to $57.00. On average, they expect Urogen Pharma's share price to reach $45.20 in the next year. This suggests a possible upside of 81.7% from the stock's current price. View analysts' price targets for Urogen Pharma.

Has Urogen Pharma been receiving favorable news coverage?

Press coverage about URGN stock has trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urogen Pharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Urogen Pharma.

Who are some of Urogen Pharma's key competitors?

What other stocks do shareholders of Urogen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Urogen Pharma investors own include Crispr Therapeutics (CRSP), Micron Technology (MU), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Gilead Sciences (GILD), Kite Pharma (KITE), NVIDIA (NVDA), Exelixis (EXEL), ImmunoGen (IMGN) and Selecta Biosciences (SELB).

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the following people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $24.88.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $519.92 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.

What is Urogen Pharma's official website?

The official website for Urogen Pharma is www.urogen.com.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.